Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of NeuroVax, a Therapeutic TCR Peptide Vaccine in Relapsing Remitting Multiple Sclerosis
2006-003384-30Phase 2Completed
- Sponsor
- The Immune Response Corporation
- Start
- Nov 2006
- Modality
- Vaccines & Immunotherapeutics, Peptides
- Countries
- 1
01
Overview
Phase 2 trial of IR208 in multiple sclerosis (MS), sponsored by The Immune Response Corporation. Primary endpoint: Cumulative number of new gadolinium-enhancing brain MRI lesions. Started Nov 2006; status: completed.
02
Drugs
IR208
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2006-003384-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003384-30.